Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1994 Sep;49(9):920–921. doi: 10.1136/thx.49.9.920

Atrial natriuretic peptide levels in the sleep apnoea/hypopnoea syndrome.

T W Mackay 1, M F Fitzpatrick 1, S Freestone 1, M R Lee 1, N J Douglas 1
PMCID: PMC475196  PMID: 7940435

Abstract

BACKGROUND--Patients with the sleep apnoea/hypopnoea syndrome have increased salt and water excretion at night which has been reported to be associated with an increase in plasma levels of atrial natriuretic peptide (ANP). A study was performed to determine whether any rise in plasma ANP levels was related to nocturnal hypoxaemia. METHODS--Nine patients with sleep apnoea/hypopnoea syndrome were studied on two nights, one breathing air and the other 28% oxygen, the order being randomised. Venous levels of ANP, aldosterone, and renin activity were measured. RESULTS--No decrease in plasma ANP levels on oxygen was seen, and, indeed, there was no evidence of an overnight increase in ANP levels. CONCLUSION--Oxygen therapy does not diminish nocturnal plasma ANP levels in patients with sleep apnoea/hypopnoea syndrome.

Full text

PDF
920

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANTON A. H., SAYRE D. F. THE DISTRIBUTION OF DOPAMINE AND DOPA IN VARIOUS ANIMALS AND A METHOD FOR THEIR DETERMINATION IN DIVERSE BIOLOGICAL MATERIAL. J Pharmacol Exp Ther. 1964 Sep;145:326–336. [PubMed] [Google Scholar]
  2. Baruzzi A., Riva R., Cirignotta F., Zucconi M., Cappelli M., Lugaresi E. Atrial natriuretic peptide and catecholamines in obstructive sleep apnea syndrome. Sleep. 1991 Feb;14(1):83–86. doi: 10.1093/sleep/14.1.83. [DOI] [PubMed] [Google Scholar]
  3. Cheshire K., Engleman H., Deary I., Shapiro C., Douglas N. J. Factors impairing daytime performance in patients with sleep apnea/hypopnea syndrome. Arch Intern Med. 1992 Mar;152(3):538–541. [PubMed] [Google Scholar]
  4. Douglas N. J., Thomas S., Jan M. A. Clinical value of polysomnography. Lancet. 1992 Feb 8;339(8789):347–350. doi: 10.1016/0140-6736(92)91660-z. [DOI] [PubMed] [Google Scholar]
  5. Douglas N. J., Thomas S., Jan M. A. Clinical value of polysomnography. Lancet. 1992 Feb 8;339(8789):347–350. doi: 10.1016/0140-6736(92)91660-z. [DOI] [PubMed] [Google Scholar]
  6. Freestone S., Jeffrey R. F., Bonner C. V., Lee M. R. Effect of lithium on the renal actions of alpha-human atrial natriuretic peptide in normal man. Clin Sci (Lond) 1990 Apr;78(4):371–375. doi: 10.1042/cs0780371. [DOI] [PubMed] [Google Scholar]
  7. Guilleminault C., Tilkian A., Dement W. C. The sleep apnea syndromes. Annu Rev Med. 1976;27:465–484. doi: 10.1146/annurev.me.27.020176.002341. [DOI] [PubMed] [Google Scholar]
  8. Haber E., Koerner T., Page L. B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969 Oct;29(10):1349–1355. doi: 10.1210/jcem-29-10-1349. [DOI] [PubMed] [Google Scholar]
  9. Krieger J., Follenius M., Sforza E., Brandenberger G., Peter J. D. Effects of treatment with nasal continuous positive airway pressure on atrial natriuretic peptide and arginine vasopressin release during sleep in patients with obstructive sleep apnoea. Clin Sci (Lond) 1991 May;80(5):443–449. doi: 10.1042/cs0800443. [DOI] [PubMed] [Google Scholar]
  10. Krieger J., Imbs J. L., Schmidt M., Kurtz D. Renal function in patients with obstructive sleep apnea. Effects of nasal continuous positive airway pressure. Arch Intern Med. 1988 Jun;148(6):1337–1340. [PubMed] [Google Scholar]
  11. Krieger J., Laks L., Wilcox I., Grunstein R. R., Costas L. J., McDougall J. G., Sullivan C. E. Atrial natriuretic peptide release during sleep in patients with obstructive sleep apnoea before and during treatment with nasal continuous positive airway pressure. Clin Sci (Lond) 1989 Oct;77(4):407–411. doi: 10.1042/cs0770407. [DOI] [PubMed] [Google Scholar]
  12. Krieger J., Schmidt M., Sforza E., Lehr L., Imbs J. L., Coumaros G., Kurtz D. Urinary excretion of guanosine 3':5'-cyclic monophosphate during sleep in obstructive sleep apnoea patients with and without nasal continuous positive airway pressure treatment. Clin Sci (Lond) 1989 Jan;76(1):31–37. doi: 10.1042/cs0760031. [DOI] [PubMed] [Google Scholar]
  13. Lin C. C., Tsan K. W., Lin C. Y. Plasma levels of atrial natriuretic factor in moderate to severe obstructive sleep apnea syndrome. Sleep. 1993 Jan;16(1):37–39. doi: 10.1093/sleep/16.1.37. [DOI] [PubMed] [Google Scholar]
  14. Partinen M., Telakivi T., Kaukiainen A., Salmi T., Färkkilä M., Saijonmaa O., Fyhrquist F. Atrial natriuretic peptide in habitual snorers. Ann Med. 1991 Apr;23(2):147–151. doi: 10.3109/07853899109148039. [DOI] [PubMed] [Google Scholar]
  15. Warley A. R., Stradling J. R. Abnormal diurnal variation in salt and water excretion in patients with obstructive sleep apnoea. Clin Sci (Lond) 1988 Feb;74(2):183–185. doi: 10.1042/cs0740183. [DOI] [PubMed] [Google Scholar]
  16. Whyte K. F., Allen M. B., Jeffrey A. A., Gould G. A., Douglas N. J. Clinical features of the sleep apnoea/hypopnoea syndrome. Q J Med. 1989 Jul;72(267):659–666. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES